Prospects for p53-based cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The p53 tumor suppressor protein acts as a cellular hub, integrating stress signals like DNA damage and hypoxia.
• p53 primarily functions as a transcription factor, inducing outcomes such as cell cycle arrest and apoptosis.
• Dysregulation of p53 or its pathway is frequent in malignant transformations, with p53 gene mutations found in approximately half of human tumors.

Purpose of the Study:

• To highlight the critical role of p53 in cellular responses to stress.
• To emphasize the significance of p53 pathway dysfunction in cancer development.
• To discuss the therapeutic potential of targeting p53 for anticancer drug design.

Main Methods:

• Review of p53's function as a transcription factor.
• Analysis of p53's role in cell cycle arrest and apoptosis.
• Examination of p53 mutations in human tumors.
• Discussion of current strategies for restoring wild-type p53 activity.

Main Results:

• p53 is a key mediator of cellular stress responses, including DNA repair and apoptosis.
• Mutations in the p53 gene are highly prevalent in human cancers, often contributing to tumor progression.
• Mutant p53 can gain oncogenic functions, further promoting cancer development.
• Restoring wild-type p53 conformation and activity is a viable therapeutic strategy.

Conclusions:

• p53 is a critical tumor suppressor frequently inactivated in cancer.
• Targeting p53 dysfunction with small molecule drugs represents a promising avenue for cancer therapy.
• Developing drugs that restore wild-type p53 function holds significant potential for treating human tumors.